ROR1 for Lymphoid Cancers

Stephen J Schuster

doi:10.1056/EVIDe2100014

ROR1 for Lymphoid Cancers

NEJM Evid. 2022 Jan;1(1):EVIDe2100014. doi: 10.1056/EVIDe2100014. Epub 2022 Jan 10.

Author

Stephen J Schuster^{1

2}

Affiliations

¹ Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
² Division of Hematology-Oncology, University of Pennsylvania, Philadelphia.

PMID: 38319244
DOI: 10.1056/EVIDe2100014

Abstract

ROR1 for Lymphoid Cancers This editorial discusses the first-in-human, phase 1 clinical trial of a novel antibody-drug conjugate, zilovertamab vedotin, in patients with relapsed or refractory mature B-cell malignancies.

Publication types

Editorial

MeSH terms

Humans
Immunoconjugates / therapeutic use
Receptor Tyrosine Kinase-like Orphan Receptors* / genetics
Receptor Tyrosine Kinase-like Orphan Receptors* / metabolism

Substances

Receptor Tyrosine Kinase-like Orphan Receptors
ROR1 protein, human
Immunoconjugates